Tag Archives: NASH

Setting The Pace In The Race To Treat NASH
December 9, 2015

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. It is the holiday season and as we gorge on delicious and heavy food, and inevitably resolve to eat less

7 Comments

From Crawl to Sprint: The Race to Treat NASH
May 21, 2015

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. Early this week, Intercept Pharmaceuticals announced the much awaited design of their Ph. 3 clinical trial of Obeticholic Acid (OCA)

2 Comments

FLINT, NASH, And Biotech: How Big Things Happen
May 6, 2014

On January 9th, 2014, Intercept Pharmaceuticals (ICPT) released a very interesting piece of news regarding their Phase 2 FLINT (Farnesoid X Receptor Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis Treatment) trial.  FLINT, a test of their FXR agonist obeticholic acid (OCA)

Leave a comment